Evidence map›Paper›PMID 36710485›Full record

ArticleThe clinical respiratory journal2023

Prognostic prediction of lung adenocarcinoma by integrative analysis of RHOH expression and methylation.

Muyu Kuang, Zhenhua Zhou, Zhongyuan Lu, Weina Shen, Haiyan Ge, Xiaoting Tao, Yue Zhao, Lingdun Zhuge, Yihua Sun, Dongmei Ji and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The clinical respiratory journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Muyu KuangPhase I Clinical Trial Center, Fudan University Shanghai Cancer Center, Shanghai, China.
Zhenhua ZhouDepartment of Orthopaedic Oncology, Changzheng Hospital, Naval Military Medical University, Shanghai, China.
Zhongyuan LuDepartment of Thoracic Surgery, 903th Hospital of PLA, Hangzhou, China.
Weina ShenPhase I Clinical Trial Center, Fudan University Shanghai Cancer Center, Shanghai, China.
Haiyan GeDepartment of Pulmonary Diseases, Huadong Hospital, Shanghai, China.
Xiaoting TaoDepartment of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Yue ZhaoDepartment of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Lingdun ZhugeDepartment of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Yihua SunDepartment of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Dongmei JiDepartment of Head & Neck tumors and Neuroendocrine tumors, Fudan University Shanghai Cancer Center, Shanghai, China.
Huibiao ZhangDepartment of Thoracic Surgery, Huadong Hospital, Shanghai, China.ORCID https://orcid.org/0000-0001-5914-9959
Fudan University Shanghai Cancer Center · CNHuadong Hospital · CN117th Hospital of People's Liberation Army · CNShanghai Changzheng Hospital · CN

Funding

Research Foundation of Huadong Hospital 2019jc006
6 · The paper itself

Abstract

BACKGROUND AND

objectiveThe development of epigenetics holds great promise for diagnosis and treatment of lung adenocarcinoma (LUAD). The purpose of this work was to analyze the correlation between Ras Homolog Gene Family Member H (RHOH) expression and methylation in patients with LUAD and its association with survival.

methodsData related to gene expression, DNA methylation, and clinical features of LUAD from The Cancer Genome Atlas (TCGA) database were analyzed. A total of 50 patients were included in verification group. The methylation level of RHOH in verification group was detected by bisulfite amplicon sequencing.

resultsThe RHOH methylation level in TCGA cohort was significantly and negatively correlated with its expression level (Cor = -0.5, p = 2.687e-33). Patients with hypermethylation and low expression of RHOH had significantly worse prognosis than patients with hypomethylation and low expression of RHOH (TCGA: p = 0.004; validation cohort: p = 0.006, HR: 4.740, 95% CI: 1.567-14.340).

conclusionOur research revealed that RHOH may prove to be a new potential prognostic predictor for LUAD patients.

Indexed as

Adenocarcinoma of LungLung NeoplasmsBiomarkers, TumorDNA MethylationHumansPrognosisrho GTP-Binding ProteinsTranscription FactorsBiomarkers, Tumorrho GTP-Binding ProteinsRhoH protein, humanTranscription Factorslung adenocarcinomamethylationprognosisRHOHTCGA

Identifiers

PMID36710485
PMCPMC9978903
OpenAlexW4318460691

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.